Establishment of a biobank and pharmacogenetics database of African populations

European Journal of Human Genetics

Volumn 16, Issue 7, 2008, Pages 780-783

  Matimba, Alice ^a   Oluka, Margaret N ^b   Ebeshi, Benjamin U ^c   Sayi, Jane ^d   Bolaji, Oluseye O ^c   Guantai, Anastasia N ^b   Masimirembwa, Collen M ^a  

^a African Institute of Biomedical Science and Technology   (Zimbabwe)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^d MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; EFAVIRENZ; NEUROLEPTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; AUTOMATION; BIOINFORMATICS; BLOOD BANK; BLOOD SAMPLING; COMPUTER PROGRAM; DNA DETERMINATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; ETHNICITY; GENE FREQUENCY; GENETIC DATABASE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE FACILITY; HOMOZYGOSITY; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERNET; LOW DRUG DOSE; MOLECULAR BIOLOGY; MOLECULAR EVOLUTION; PATENT; PHARMACOGENETICS; POPULATION GENETICS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL SPECIMEN BANKS; DATABASES, GENETIC; GENE FREQUENCY; GEOGRAPHY; HUMANS; PHARMACOGENETICS;

EID: 45049083067     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2008.49     Document Type: Article

References (22)

1. Evans WE: PhMrmacogenomics: marshalling the human genome to individualise drug therapy. Gut 2003; 52 (Suppl 2): ii10-ii18.
2. Sgaier SK, Jha P, Mony P et al: Public health. Biobanks in developing countries: Needs and feasibility. Science 2007; 318 1074-1075.
3. Aklillu E, Dandara C, Bertilsson L, Masimirembwa C: Pharmacogenetics of cytochrome P450s in African populations: Clinical and molecular evolutionary implications.In: Suarez-Kurtz G (ed).: Pharmacogenomics in Admixed Populations. Texas, USA: Landes Bioscience, 2007.
4. Abe M, Suzuki T, Deguchi T: An improved method for genotyping of N acetyltransferase polymorphism by polymerase chain reaction. Jpn J Hum Genet 1993; 38: 163-168.
5. Bell DA, Taylor JA, Butler MA et al: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14: 1689-1692.
6. Brockmoller J, Gross D, Kerb R, Drakoulis N, Roots I: Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reaction. Biochem Pharmacol 1992; 43: 647-650.
7. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-15422.
8. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS: Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999; 9: 669-682.
9. Pemble S, Schroeder KR, Spencer SR et al: Human glutathione S transferase theta (GSTT1): CDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300 (Part 1): 271-276.
10. Rotger M, Colombo S, Furrer H et al: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15: 1-5.
11. Cavalli-Sforza LL: The Human GPnome Diversity Project: past, present and future. Nat Rev Genet 2005; 6: 333-340.
12. Rosenberg NA, Pritchard JK, Weber JL et al: Genetic structure of human populations. Science 2002; 298: 2381-2385.
13. Agyemang C, Bhopal R, Bruijnzeels M: Negro, Black, Black African, African Caribbean, African American or what? Labelling African origin populations in the health arena in the 21st century. J Epidemiol Community Health 2005; 59: 1014-1018.
14. Ely B, Wilson JL, Jackson F, Jackson BA: African-American mitochondrial DNAs often match mtDNAs found in multiple African ethnic groups. BMC Biol 2006; 4: 34.
15. Sirugo G, Schim vdL, Sam O et al: A national DNA bank in the Gambia, West Africa, and genomic research in developing countries. Nat Genet 2004; 36: 785-786.
16. Kaiser J: Genomic medicine. African-American population biobank proposed. Science 2003; 300: 1485.
17. Klein K, Lang T, Saussele T et al: Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15: 861-873.
18. Nolan D, Phillips E, Mallal S: Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin Infect Dis 2006; 42: 408-410.
19. Rodriguez-Novoa S, Barreiro P, Jimenez-Nacher I, Soriano V: Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J 2006; 6 234-245.
20. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M: A novel mutant variant of the CYP2D6 gene (CYP2D6 17) common in a black African population: Association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42: 713-719.
21. Kirchheiner J, Brosen K, Dahl ML et al: CYP2D6 And CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards, subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-192.
22. Masimirembwa CM, Hasler JA: Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants. Brain Res Bull 1997; 44: 561-571.